November 16, 2022

To	To
Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir/ Madam,

Sub: Conclusion of US FDA Inspection at our Unit XI – Reg.,
Ref: Our Letters dated May 17, 2019, June 21, 2019 and Aug 2, 2022

Pursuant to Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 and further to our above referred letters, this is to inform you that:

The Company's Unit XI, an API Non-antibiotic manufacturing facility situated at Pydibhimavaram, Srikakulam District, Andhra Pradesh was inspected by the United States Food and Drug Administration (USFDA) in February 2019 and issued a warning letter in June 2019 and this Unit was further inspected by USFDA from 25th July to 2nd August 2022 and issued a Form 483 with 3 observations. All these developments have been duly intimated to Stock Exchanges vide our letters referred to above.

Subsequent to our responses for the aforesaid observations, we have received an Establishment Inspection Report (EIR) classifying the inspection as Voluntary Action Indicated (VAI) from the US FDA and with this, the inspection at our Unit XI is concluded.

We request you to kindly take the above information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED

Digitally signed by
ADIREDDY BADDIGAM
Date: 2022.11.16 17:15:39
+05'30'

B. Adi Reddy
Company Secretary